Cue Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Cue Biopharma, Inc. on February 18, 2026. The filing announces the date for the Company's 2026 Annual Meeting of Stockholders and outlines the deadlines for stockholder proposals and director nominations.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural notice regarding corporate governance and does not contain financial performance data.
Material Changes
No material financial changes or operational updates are reported in this filing. The document solely addresses the scheduling of the upcoming annual meeting and the procedural requirements for stockholder engagement.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors. It details the following procedural deadlines for the 2026 Annual Meeting scheduled for April 13, 2026:
- Stockholder Proposals (Rule 14a-8): Must be received by February 28, 2026, to be considered for inclusion in the proxy statement.
- Director Nominations and Other Matters (Bylaws): Notice must be received by February 28, 2026.
- Universal Proxy Rule (Rule 14a-19): Notice for soliciting proxies for director nominees other than the Company's nominees must be received by February 28, 2026.
Key Facts for Investor Verification
- Annual Meeting Date: April 13, 2026.
- Proposal Deadline: February 28, 2026, for all stockholder proposals and director nominations.
- Consequence of Missing Deadline: If notice is not provided by the deadline, the Board's proxies may exercise discretionary voting power on the matter.
- Trading Symbol: CUE on the Nasdaq Capital Market.